interview with peter cook, page-6

It will be interesting if it is licensed to Roche.
Roche will have two and ONLY anti-viral products, which becomes Monopoly in this Market. Everyone know what a monopoly role means.
If GSK does not get the license, Relenza will soon be obsolete. As shareholders of a Junior Australian Company,we already learned lesson from this GIANT, the second largest pharmaceutical. GSK needs to convince all the BTA shareholders that they will do as Roche does to promote LANI. It's pretty hard for them to achieve it.
As for the third seriously interested company, I suspect it's Daiichi Sankyo. DS will do its best best to sell LANI all over the world. Don't know whether DS has a distribution chain worldwide, however, if swine or bird flu turned more virulent, it's not a major issue.
Let's hope our BTA management get a good deal this time.